Coronavirus pandemic brings importance of immunisation to the fore; MMR or BCG vaccine may protect against severe COVID-19
The importance of immunisation has probably never seemed as important as it does during this pandemic.
Timely and effective immunisation is considered to be a very important step in reducing an individual’s risk of getting infectious diseases. If you are immunised, you are also saving your immediate family and close ones from getting infections frequently.
The importance of immunisation has probably never seemed as important as it does during this pandemic. Earlier in April, it was proposed that in the areas where mass immunisation with the BCG (Bacillus Calmette Guerin) vaccine was conducted, the virus seemed to have been spreading at a slower speed.
Shortly after that, a group of researchers at the University of Cambridge declared that an MMR (measles, mumps and rubella) vaccine can provide you with some amount of immunity against SARS-CoV-2, the causative agent of COVID-19.
Now, a group of experts from the American Society for Microbiology have claimed that an MMR vaccine can reduce inflammation associated with COVID-19 and hence can be a reason why children get a milder disease. It can also offer protection to adults who have gotten a booster shot.
BCG and MMR
The BCG vaccine is a live attenuated vaccine which contains the weakened version of the Mycobacterium Bovis bacteria. BCG has been discontinued in various areas in the world now due to a reduction in Tuberculosis (TB) cases. India still has a compulsory vaccination for BCG since TB is prevalent in the country. The vaccine is given at the time of birth.
The MMR vaccine is yet another liver attenuated vaccine that protects against three different viral diseases - measles, mumps and rubella. According to the Indian Academy of Pediatrics, all children should get an MMR shot at 9 months of age, 15 months and between 4-6 years.
Non-specific effects of vaccines
The terms ‘non-specific; or ‘heterologous’ effects of a vaccine are used to refer to vaccines that have an effect on pathogens other than the one they were originally targetted to fight.
For example, the BCG vaccine not only provides immunity against TB but also other Mycobacteria like M.leprae, the causative agent of leprosy. Even when the vaccine first showed up, it was noted that children who got a BCG shot had a lesser risk of mortality as compared to those who do not and this could not be explained by only protection from TB. Clinical trials show that BCG vaccine reduces mortality from various types of infections like, for example, yellow fever.
As per a study published in The Lancet, the effect of BCG vaccine can be attributed to it being a live attenuated vaccine. These vaccines train our immune system in such a way that it is better able to fight all kinds of infections. Clinical studies are underway to check the effects of BCG vaccine against SARS-CoV-2.
Similar non-specific immunity has previously been found with the MMR vaccine.
The MMR vaccine and SARS-CoV-2
As per a preprint paper, there are various reasons an MMR vaccine may be able to protect against the coronavirus. These include similarities in a part of the protein structure of rubella, measles and mumps virus with that of SARS-CoV-2. A protein domain of rubella virus was found to have 29 percent similarity with that of the COVID-19 causing virus. The study had also suggested that older people and men who had lesser rubella antibodies were more likely to die of COVID-19. It was concluded that the vaccine may not prevent SARS-CoV-2 but would certainly lead to a milder disease.
The latest research by the American Society for Microbiology also suggested the idea of non-specific immunity as the protective factor in septic inflammation in COVID-19 patients. In their paper published in the British Medical Journal, Dr Paul Fidel, Jr, Department Chair at the Department of Oral and Craniofacial Biology, and Associate Dean for Research, Louisiana State University Health School of Dentistry, wrote that live attenuated vaccines train the precursors of white blood cells (myeloid-derived suppressor cells) in the bone marrow to work against a wide variety of pathogens. The myeloid-derived suppressor cells are long-lived cells that have the ability to inhibit inflammation.
With time, the myeloid-derived suppressor cells may not be seen in the body though. So, for the vaccine to still work, you may have to get a booster shot.
For more information, read our article on Immunity to COVID-19.
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
US study claims low dose radiation therapy could help treat pneumonia in COVID-19 patients; results under peer review
Preliminary results of a US study showed that within 24 hours of receiving low-dose radiation therapy, four COVID-19 patients with pneumonia showed rapid improvement in their breathing
COVID-19 origin: University of Calgary research shows SARS-CoV-2 may have been evolving slowly since 2013
Scientists at the University of Calgary in Canada say that the novel coronavirus (SARS-CoV-2) may have been circulating amongst humans since at least 2013, though not the same variant that is responsible for the COVID-19 pandemic
COVID-19 treatment: Study suggests cellular nanosponges could restrict SARS-CoV-2 virus multiplication; animal trials underway
Studies conducted by researchers at UC San Diego showed that cellular nanosponges could reduce the ability of SARS-CoV-2 virus that causes COVID-19 disease to infect host cells